Virax Biolabs Files September 2024 6-K Report

Ticker: VRAX · Form: 6-K · Filed: Sep 30, 2024 · CIK: 1885827

Virax Biolabs Group Ltd 6-K Filing Summary
FieldDetail
CompanyVirax Biolabs Group Ltd (VRAX)
Form Type6-K
Filed DateSep 30, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001, $2,879,117, $779,336
Sentimentneutral

Sentiment: neutral

Topics: 6-K, reporting, foreign-private-issuer

TL;DR

Virax Biolabs filed its monthly 6-K, confirming its reporting status and basic company info.

AI Summary

Virax Biolabs Group Ltd. filed a Form 6-K on September 30, 2024, reporting for the month of September 2024. The company, previously known as Virax Biolabs (Cayman) Ltd. until September 30, 2021, is incorporated in E9 and has a fiscal year end of March 31. Its principal executive offices are located at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH, United Kingdom.

Why It Matters

This filing provides routine updates and confirms the company's reporting status with the SEC, which is important for investors tracking its compliance and operational information.

Risk Assessment

Risk Level: low — This is a routine filing that does not contain new material financial information or significant operational changes.

Key Players & Entities

  • Virax Biolabs Group Ltd (company) — Registrant
  • Virax Biolabs (Cayman) Ltd (company) — Former company name
  • BioCity Glasgow (company) — Location of principal executive offices
  • September 30, 2024 (date) — Filing date
  • September 2024 (date) — Reporting period

FAQ

What is the primary purpose of this Form 6-K filing?

This Form 6-K is a report of a foreign private issuer for the month of September 2024, used to provide information to the SEC.

When was Virax Biolabs Group Ltd. previously known by another name?

The company was formerly known as Virax Biolabs (Cayman) Ltd. until September 30, 2021.

Where are Virax Biolabs Group Ltd.'s principal executive offices located?

The principal executive offices are located at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH, United Kingdom.

What is the fiscal year end for Virax Biolabs Group Ltd.?

The fiscal year end for Virax Biolabs Group Ltd. is March 31.

Does Virax Biolabs Group Ltd. file annual reports on Form 20-F or 40-F?

Yes, the company indicates it files annual reports under cover of Form 20-F.

Filing Stats: 649 words · 3 min read · ~2 pages · Grade level 13.8 · Accepted 2024-09-30 09:14:19

Key Financial Figures

  • $0.001 — s Agent, its ordinary shares, par value $0.001 per share (the “ Ordinary Shares
  • $2,879,117 — ent under the Sales Agreement, to up to $2,879,117 (which amount does not include $779,336
  • $779,336 — ,879,117 (which amount does not include $779,336 of Ordinary Shares previously sold by t

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: September 30, 2024 By: /s/ James Foster James Foster, Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.